ArticleAnnals of internal medicine2022
In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status.
Marat Fudim et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
ArticleAnnals of internal medicine2022
Marat Fudim et al.PubMed ↗Publisher ↗
No numbers read from the abstract.